Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price LOS ANGELES, CA / ACCESS Newswire / September 24, 2025 / Lunai Bioworks, Inc. (Nasdaq:RENB) ("Lunai Bioworks" or the "Company"), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that the Company's Board of Directors has approved a 10:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") to be effective 12:01 ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Tuesday, Cathie Wood-led Ark Invest made a notable decision by selling shares of Tempus AI Inc. (NASDAQ:TEM), marking a significant move in their investment strategy. The Tempus AI Trade Ark Invest sold 62,352 shares of Tempus AI (Pre-Reincorporation) through the ARK Innovation ETF (BATS:ARKK). The shares were sold at a closing price of $84.13, amounting to a transaction value of approximately $5.2 mill ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Sep 24, 2025 4:16 PM Eastern Daylight Time PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients Share – 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity – BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation o ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the “Offering”). In addition, Immuneering intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of Class A common stock eq ...

- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on k ...

Wave Life Sciences (NasdaqGM:WVE) FY Conference September 24, 2025 02:50 PM ET Company ParticipantsErik Ingelsson - Chief Scientific OfficerConference Call ParticipantsWilliam Pickering - Senior AnalystWilliam PickeringGood afternoon, everyone. Thanks so much for joining. My name is Will Pickering. I cover U.S. biotech at Bernstein. I'm very pleased to be joined today by Dr. Erik Ingelsson from Wave Life Sciences. Erik, thanks so much. Maybe let me hand it over to you for an introduction of the company.Erik ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

Question-and-Answer SessionPriya SinghalExecutive VP & Head of Development Yes, we've been very excited to create the new Biogen. And I'm really pleased because I think we are well on our way. And I'll start with the fact that from a commercial perspective, the Alzheimer's launch, we are seeing some inflection points in the LEQEMBI launch. This is important because we just got approval for subcutaneous maintenance, which we think is a very important option for patients. And we've also begun our rolling subm ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Wednesday.The Dow traded down 0.35% to 46,129.26 while the NASDAQ fell 0.47% to 22,468.39. The S&P 500 also fell, dropping, 0.40% to 6,630.54.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsEnergy shares jumped by 1.9% on Wednesday.In trading on Tuesday, materials stocks fell by 1.5%.Top HeadlineCrude oil inventories in the U.S. declined by 0.607 million barrels i ...